Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cowealth Medical Holding Co., Ltd. (4745:TWSE), powered by AI.
Cowealth Medical Holding Co., Ltd. is currently trading at $14.60. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cowealth Medical Holding Co., Ltd. on Alpha Lenz.
Cowealth Medical Holding Co., Ltd.'s P/E ratio is -4.6.
“Cowealth Medical Holding Co., Ltd. trades at a P/E of -4.6 (undervalued) with modest ROE of -8.7%.”
Ask for details →Cowealth Medical Holding Co., Ltd. is a holding company specializing in the manufacture and distribution of advanced medical equipment, devices, and related products. Its primary purpose is to provide innovative healthcare solutions across Greater China, serving hospitals and clinical laboratories with a focus on cancer treatment systems, in-vitro diagnostic reagents, and high-end clinical testing technology. The company’s portfolio includes notable devices such as the CyberKnife Stereotactic Radiosurgery System for radiation therapy and the MRIdian-Linac MRI-guided system, as well as comprehensive diagnostic tools and reagents. Beyond direct product distribution, Cowealth Medical Holding Co., Ltd. supports the healthcare sector through digital innovations, including platforms for management analysis, multi-channel audio-video imaging, and AI-assisted clinical decision support, all designed to enhance medical resource efficiency and hospital competitiveness. With operations in Taiwan, China, and Hong Kong, Cowealth Medical Holding Co., Ltd. plays a significant role in elevating healthcare standards by bridging technological advancements and tailored service models in the rapidly evolving healthcare industry.
“Cowealth Medical Holding Co., Ltd. trades at a P/E of -4.6 (undervalued) with modest ROE of -8.7%.”
Ask for details →Cowealth Medical Holding Co., Ltd. (ticker: 4745) is a company listed on TWSE in the Healthcare sector (Medical Devices). Market cap is $1.1B.
The current price is 14.6 with a P/E ratio of -4.59x and P/B of 0.39x.
ROE is -8.70% and operating margin is -6.07%. Annual revenue is $3.0B.